Testing effectiveness (Phase 2)Study completedNCT02859441
What this trial is testing
A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab
Who this might be right for
Von Hippel-Lindau Syndrome
National Eye Institute (NEI) 3